• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Lung cancer (non-small-cell) - pemetrexed

Pemetrexed for the treatment of non-small cell lung cancer

Status:	History
Expected date of issue:	August 2007
Wave:	TBC
Process:	STA
Topic area: Cancer Respiratory Therapeutic procedures

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Communications manager:	Phil Ranson
Project manager:	Chris Feinmann
Evidence review group:	Liverpool Reviews and Implementation Group (LRiG), University of Liverpool

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	29 June 2006
1st appraisal committee meeting:	11 October 2006
2nd appraisal committee meeting	TBC

Top

 

Consultees and commentators

Consultees Commentators (no right of appeal) Manufacturers / Sponsors Eli Lilly and Company Ltd Patient / Carer Groups CancerBACKUP Roy Castle Lung Cancer Foundation Tenovus Cancer Information Centre Professional Groups British Thoracic Society Cancer Networks Pharmacists Forum Cancer Research UK Royal College of Nursing RoyalCollegeof Pathologists RoyalCollegeof Physicians (Medical Oncology Joint Special Committee) RoyalCollegeof Radiologists Royal Pharmaceutical Society Others Department of Health Welsh Assembly Government General British National Formulary NHS Quality Improvement Scotland Comparator Manufacturers Roche Products Ltd Sanofi-Aventis Evidence Review Groups Liverpool Reviews and Implementation Group , University of Liverpool National Coordinating Centre for Health Technology Assessment Associated Guideline Groups National Collaborating Centre for Cancer Associated Public Health Groups None Research Groups British Thoracic Oncology Group MRC CTU - Lung Cancer and Mesothelioma Group

Top

 

Project history

Date Update 10 April 2006 Project team and schedule added. 8 September 2006 List of consultees and commentators added. 22 September 2006 Project team and schedule updated. 23 November 2006 Stakeholders updated. 28 February 2007 Schedule updated.

Top

 

Key documents

Lung cancer (non-small cell) - pemetrexed: appeal documents 04 June 2007 Lung cancer (non-small cell) - pemetrexed: Result of appeal 22 August 2007 Pemetrexed for the treatment of non-small-cell lung cancer: Appeal 01 May 2007 Pemetrexed for the treatment of non-small-cell lung cancer: Appeal announcement 20 April 2007 Lung cancer (non-small cell) - pemetrexed: final appraisal determination 15 February 2007 Pemetrexed for the treatment of non-small-cell lung cancer (appraisal consultation document) 13 November 2006 Lung cancer (non-small cell) - erlotinib and pemetrexed (original MTA) 22 June 2005

This page was last updated: 30 March 2010